YKL-40 tissue expression and plasma levels in patients with ovarian cancer

Estrid V S Høgdall; Merete Ringsholt; Claus K Høgdall; Ib Jarle Christensen; Julia S Johansen; Susanne K Kjaer; Jan Blaakaer; Lene Ostenfeld-Møller; Paul A Price; Lise H Christensen

doi:10.1186/1471-2407-9-8

YKL-40 tissue expression and plasma levels in patients with ovarian cancer

Estrid V S Høgdall, Merete Ringsholt, Claus K Høgdall, Ib Jarle Christensen, Julia S Johansen, Susanne K Kjaer, Jan Blaakaer, Lene Ostenfeld-Møller, Paul A Price, Lise H Christensen

Section of Biostatistics

55 Citations (Scopus)

Abstract

BACKGROUND: YKL-40 (chitinase-3-like-1) is a member of "mammalian chitinase-like proteins". The protein is expressed in many types of cancer cells and the highest plasma YKL-40 levels have been found in patients with metastatic disease, short recurrence/progression-free intervals, and short overall survival. The aim of the study was to determine the expression of YKL-40 in tumor tissue and plasma in patients with borderline ovarian tumor or epithelial ovarian cancer (OC), and investigate prognostic value of this marker. METHODS: YKL-40 protein expression was determined by immunohistochemistry in tissue arrays from 181 borderline tumors and 473 OC. Plasma YKL-40 was determined by ELISA in preoperative samples from 19 patients with borderline tumor and 76 OC patients. RESULTS: YKL-40 protein expression was found in cancer cells, tumor associated macrophages, neutrophils and mast cells. The tumor cell expression was higher in OC than in borderline tumors (p = 0.001), and associated with FIGO stage (p < 0.0001) and histological subtype (p = 0.0009). Positive YKL-40 expression (>or= 5% staining) was not associated with reduced survival. Plasma YKL-40 was also higher in patients with OC than in patients with borderline tumors (p < 0.0001), and it was positively correlated to serum CA-125 (p < 0.0001) and FIGO stage (p = 0.0001). Univariate Cox analysis of plasma YKL-40 showed association with overall survival (p < 0.0001). Multivariate Cox analysis, including plasma YKL-40, serum CA125, FIGO stage, age and radicality after primary surgery as variables, showed that elevated plasma YKL-40 was associated with a shorter survival (HR = 2.13, 95% CI: 1.40-3.25, p = 0.0004). CONCLUSION: YKL-40 in OC tissue and plasma are related to stage and histology, but only plasma YKL-40 is a prognostic biomarker in patients with OC.

Original language	English
Journal	BMC Cancer
Volume	9
Pages (from-to)	8
ISSN	1471-2407
DOIs	https://doi.org/10.1186/1471-2407-9-8
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1471-2407-9-8

Cite this

@article{57de90706a3c11df928f000ea68e967b,

title = "YKL-40 tissue expression and plasma levels in patients with ovarian cancer",

abstract = "BACKGROUND: YKL-40 (chitinase-3-like-1) is a member of {"}mammalian chitinase-like proteins{"}. The protein is expressed in many types of cancer cells and the highest plasma YKL-40 levels have been found in patients with metastatic disease, short recurrence/progression-free intervals, and short overall survival. The aim of the study was to determine the expression of YKL-40 in tumor tissue and plasma in patients with borderline ovarian tumor or epithelial ovarian cancer (OC), and investigate prognostic value of this marker. METHODS: YKL-40 protein expression was determined by immunohistochemistry in tissue arrays from 181 borderline tumors and 473 OC. Plasma YKL-40 was determined by ELISA in preoperative samples from 19 patients with borderline tumor and 76 OC patients. RESULTS: YKL-40 protein expression was found in cancer cells, tumor associated macrophages, neutrophils and mast cells. The tumor cell expression was higher in OC than in borderline tumors (p = 0.001), and associated with FIGO stage (p < 0.0001) and histological subtype (p = 0.0009). Positive YKL-40 expression (>or= 5% staining) was not associated with reduced survival. Plasma YKL-40 was also higher in patients with OC than in patients with borderline tumors (p < 0.0001), and it was positively correlated to serum CA-125 (p < 0.0001) and FIGO stage (p = 0.0001). Univariate Cox analysis of plasma YKL-40 showed association with overall survival (p < 0.0001). Multivariate Cox analysis, including plasma YKL-40, serum CA125, FIGO stage, age and radicality after primary surgery as variables, showed that elevated plasma YKL-40 was associated with a shorter survival (HR = 2.13, 95% CI: 1.40-3.25, p = 0.0004). CONCLUSION: YKL-40 in OC tissue and plasma are related to stage and histology, but only plasma YKL-40 is a prognostic biomarker in patients with OC.",

author = "H{\o}gdall, {Estrid V S} and Merete Ringsholt and H{\o}gdall, {Claus K} and Christensen, {Ib Jarle} and Johansen, {Julia S} and Kjaer, {Susanne K} and Jan Blaakaer and Lene Ostenfeld-M{\o}ller and Price, {Paul A} and Christensen, {Lise H}",

note = "Keywords: Adult; Aged; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Lectins; Middle Aged; Ovarian Neoplasms; Prognosis; Retrospective Studies; Young Adult",

year = "2009",

doi = "10.1186/1471-2407-9-8",

language = "English",

volume = "9",

pages = "8",

journal = "B M C Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - YKL-40 tissue expression and plasma levels in patients with ovarian cancer

AU - Høgdall, Estrid V S

AU - Ringsholt, Merete

AU - Høgdall, Claus K

AU - Christensen, Ib Jarle

AU - Johansen, Julia S

AU - Kjaer, Susanne K

AU - Blaakaer, Jan

AU - Ostenfeld-Møller, Lene

AU - Price, Paul A

AU - Christensen, Lise H

N1 - Keywords: Adult; Aged; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Lectins; Middle Aged; Ovarian Neoplasms; Prognosis; Retrospective Studies; Young Adult

PY - 2009

Y1 - 2009

N2 - BACKGROUND: YKL-40 (chitinase-3-like-1) is a member of "mammalian chitinase-like proteins". The protein is expressed in many types of cancer cells and the highest plasma YKL-40 levels have been found in patients with metastatic disease, short recurrence/progression-free intervals, and short overall survival. The aim of the study was to determine the expression of YKL-40 in tumor tissue and plasma in patients with borderline ovarian tumor or epithelial ovarian cancer (OC), and investigate prognostic value of this marker. METHODS: YKL-40 protein expression was determined by immunohistochemistry in tissue arrays from 181 borderline tumors and 473 OC. Plasma YKL-40 was determined by ELISA in preoperative samples from 19 patients with borderline tumor and 76 OC patients. RESULTS: YKL-40 protein expression was found in cancer cells, tumor associated macrophages, neutrophils and mast cells. The tumor cell expression was higher in OC than in borderline tumors (p = 0.001), and associated with FIGO stage (p < 0.0001) and histological subtype (p = 0.0009). Positive YKL-40 expression (>or= 5% staining) was not associated with reduced survival. Plasma YKL-40 was also higher in patients with OC than in patients with borderline tumors (p < 0.0001), and it was positively correlated to serum CA-125 (p < 0.0001) and FIGO stage (p = 0.0001). Univariate Cox analysis of plasma YKL-40 showed association with overall survival (p < 0.0001). Multivariate Cox analysis, including plasma YKL-40, serum CA125, FIGO stage, age and radicality after primary surgery as variables, showed that elevated plasma YKL-40 was associated with a shorter survival (HR = 2.13, 95% CI: 1.40-3.25, p = 0.0004). CONCLUSION: YKL-40 in OC tissue and plasma are related to stage and histology, but only plasma YKL-40 is a prognostic biomarker in patients with OC.

AB - BACKGROUND: YKL-40 (chitinase-3-like-1) is a member of "mammalian chitinase-like proteins". The protein is expressed in many types of cancer cells and the highest plasma YKL-40 levels have been found in patients with metastatic disease, short recurrence/progression-free intervals, and short overall survival. The aim of the study was to determine the expression of YKL-40 in tumor tissue and plasma in patients with borderline ovarian tumor or epithelial ovarian cancer (OC), and investigate prognostic value of this marker. METHODS: YKL-40 protein expression was determined by immunohistochemistry in tissue arrays from 181 borderline tumors and 473 OC. Plasma YKL-40 was determined by ELISA in preoperative samples from 19 patients with borderline tumor and 76 OC patients. RESULTS: YKL-40 protein expression was found in cancer cells, tumor associated macrophages, neutrophils and mast cells. The tumor cell expression was higher in OC than in borderline tumors (p = 0.001), and associated with FIGO stage (p < 0.0001) and histological subtype (p = 0.0009). Positive YKL-40 expression (>or= 5% staining) was not associated with reduced survival. Plasma YKL-40 was also higher in patients with OC than in patients with borderline tumors (p < 0.0001), and it was positively correlated to serum CA-125 (p < 0.0001) and FIGO stage (p = 0.0001). Univariate Cox analysis of plasma YKL-40 showed association with overall survival (p < 0.0001). Multivariate Cox analysis, including plasma YKL-40, serum CA125, FIGO stage, age and radicality after primary surgery as variables, showed that elevated plasma YKL-40 was associated with a shorter survival (HR = 2.13, 95% CI: 1.40-3.25, p = 0.0004). CONCLUSION: YKL-40 in OC tissue and plasma are related to stage and histology, but only plasma YKL-40 is a prognostic biomarker in patients with OC.

U2 - 10.1186/1471-2407-9-8

DO - 10.1186/1471-2407-9-8

M3 - Journal article

C2 - 19134206

SN - 1471-2407

VL - 9

SP - 8

JO - B M C Cancer

JF - B M C Cancer

ER -

YKL-40 tissue expression and plasma levels in patients with ovarian cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this